Literature DB >> 17334399

Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells.

K Kehn1, R Berro, A Alhaj, M E Bottazzi, W-I Yeh, Z Klase, R Van Duyne, S Fu, F Kashanchi.   

Abstract

The inheritance of one defective BRCA1 or BRCA2 allele predisposes an individual to developing breast and ovarian cancers. BRCA1 is a multifunctional tumor suppressor protein, which through interaction with a vast array of proteins has implications in processes such as cell cycle, transcription, DNA damage response and chromatin remodeling. Conversely, the oncogene, cyclin D1 is overexpressed in about 35% of all breast cancer cases. In this study, we provide detailed analyses on the phosphorylation state of BRCA1 by cyclin D1/cdk4 complexes. In particular, we have identified Ser 632 of BRCA1 as a cyclin D1/cdk4 phosphorylation site in vitro. Using chromatin immunoprecipitation assays, we observed that the inhibition of cyclin D1/cdk4 activity resulted in increased BRCA1 DNA binding at particular promoters in vivo. In addition, we identified multiple novel genes that are bound by BRCA1 in vivo. Collectively, these results indicate that cyclin D1/cdk4-mediated phosphorylation of BRCA1 inhibits the ability of BRCA1 to be recruited to particular promoters in vivo. Therefore, cyclin D1/Cdk4 phosphorylation of BRCA1 could provide a mechanism to interfere with the DNA-dependent activities of BRCA1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17334399     DOI: 10.1038/sj.onc.1210319

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

Review 1.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

Review 2.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

3.  Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.

Authors:  Apichart Atipairin; Bhutorn Canyuk; Adisorn Ratanaphan
Journal:  J Biol Inorg Chem       Date:  2010-10-22       Impact factor: 3.358

Review 4.  Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.

Authors:  Neil Johnson; Geoffrey I Shapiro
Journal:  Expert Opin Ther Targets       Date:  2010-11       Impact factor: 6.902

5.  Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function.

Authors:  Irene Guendel; Lawrence Carpio; Caitlin Pedati; Arnold Schwartz; Christine Teal; Fatah Kashanchi; Kylene Kehn-Hall
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

6.  Cyclin D1 determines estrogen signaling in the mammary gland in vivo.

Authors:  Mathew C Casimiro; Chenguang Wang; Zhiping Li; Gabriele Di Sante; Nicole E Willmart; Sankar Addya; Lei Chen; Yang Liu; Michael P Lisanti; Richard G Pestell
Journal:  Mol Endocrinol       Date:  2013-07-17

Review 7.  Proteomic identification of a direct role for cyclin d1 in DNA damage repair.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; David M Livingston; Piotr Sicinski
Journal:  Cancer Res       Date:  2012-08-22       Impact factor: 12.701

8.  The antiproliferative effect of EPA in HL60 cells is mediated by alterations in calcium homeostasis.

Authors:  Jens Erik Slagsvold; Caroline Hild Hakvåg Pettersen; Turid Follestad; Hans Einar Krokan; Svanhild Arentz Schønberg
Journal:  Lipids       Date:  2008-11-20       Impact factor: 1.880

9.  Cyclin D2 is a GATA4 cofactor in cardiogenesis.

Authors:  Abir Yamak; Branko V Latinkic; Rola Dali; Rana Temsah; Mona Nemer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

10.  Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.

Authors:  Eric Tram; Sevtap Savas; Hilmi Ozcelik
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.